Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking

Commentary
Video

Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,

After observing minimal recurrence following 70 double lung resections within Northwestern’s Double lung transplant REgistry Aimed for lung-limited Malignancies (DREAM) program, Ankit Bharat, MBBS, suggested that stage IV lung cancer may be curable during an interview with CancerNetwork®.

Bharat is the chief of Thoracic Surgery in the Department of Surgery, Harold L. and Margaret N. Method Professor of Surgery, and professor of Pulmonary and Critical Care at Northwestern Medicine Feinberg School of Medicine.

Bharat suggested that patients who have exhausted all their options at a local community center would benefit from attempting to reach out to other practices, citing an instance where a patient searched across international lines to find treatment at Northwestern that ultimately saved her life. Acknowledging that not every center may provide the full scope of options for a patient with advanced cancers, he explained that patients may have to take matters into their own hands and proactively seek information themselves. He concluded by expressing that the success of the DREAM Program presents an opportunity to test the hypothesis of whether stage IV cancer is curable, challenging conventional wisdom that suggests that palliative care is the only option for these patients.

Transcript:

If patients do not have any other options left by their local center, they should do some research on their own and try to reach out [to other practices]. [One patient I had] was told nothing further could be done, but she searched and found us across international [lines]. That is the reason she is alive today.

That’s going to be important in the future, because there [is] a much freer flow of information, but [it] is a lot of information… Not every center knows everything that is out there. Patients have to take that in their own hands and [take] time to find out and seek more information, particularly when it comes to a life-saving situations.

For [our] physicians and health care [system], the fact that we have [cared for] almost 70 patients within the DREAM Program and not seen high recurrence, it does give us an opportunity to test the hypothesis that maybe stage IV cancer is curable. People think that stage IV cancer is not generally curable. You can only do palliative [treatment], but it may be possible. We have to start thinking about that. We achieve that with what we have observed based on the success of the DREAM program so far.

Recent Videos
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Related Content